Stockscreener 앱 받기
36.85
4.88%
-1.89
시간 외 거래:
37.00
0.15
+0.41%
전일 마감가:
$38.74
열려 있는:
$38.63
하루 거래량:
2.75M
Relative Volume:
1.15
시가총액:
$5.98B
수익:
$3.24B
순이익/손실:
$304.90M
주가수익비율:
17.72
EPS:
2.08
순현금흐름:
$156.70M
1주 성능:
-9.59%
1개월 성능:
-7.81%
6개월 성능:
-32.37%
1년 성능:
-51.30%
1일 변동 폭
$36.79
$38.83
1주일 범위
$36.79
$43.09
52주 변동 폭
$34.10
$79.78
Bruker Corp Stock (BRKR) Company Profile
명칭
Bruker Corp
전화
978663-3660
주소
40 MANNING RD, BILLERICA, MA
BRKR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BRKR
Bruker Corp
|
36.85 | 5.98B | 3.24B | 304.90M | 156.70M | 2.08 |
|
ABT
Abbott Laboratories
|
128.56 | 231.50B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.95 | 154.04B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
386.32 | 144.27B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
84.25 | 105.58B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
76.75 | 43.95B | 5.54B | 4.18B | 623.10M | 7.00 |
Bruker Corp Stock (BRKR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-19 | 개시 | Guggenheim | Buy |
| 2024-12-10 | 개시 | UBS | Neutral |
| 2024-12-05 | 업그레이드 | Goldman | Sell → Neutral |
| 2024-10-15 | 개시 | Barclays | Overweight |
| 2024-09-30 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-08-28 | 개시 | Wells Fargo | Overweight |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-02-14 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-12-19 | 개시 | Wells Fargo | Equal Weight |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2022-10-21 | 개시 | UBS | Buy |
| 2022-08-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-10-15 | 재개 | Cowen | Market Perform |
| 2021-06-15 | 업그레이드 | Cleveland Research | Neutral → Buy |
| 2021-02-05 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-12-02 | 개시 | Goldman | Sell |
| 2020-11-16 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2020-05-01 | 다운그레이드 | Cleveland Research | Buy → Neutral |
| 2020-04-02 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2020-04-01 | 다운그레이드 | Needham | Strong Buy → Hold |
| 2020-03-26 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-01-08 | 개시 | Wells Fargo | Overweight |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-11-15 | 개시 | Stifel | Hold |
| 2019-09-26 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-07-15 | 업그레이드 | Goldman | Sell → Neutral |
| 2019-06-24 | 재확인 | Needham | Strong Buy |
| 2019-06-21 | 재확인 | BofA/Merrill | Neutral |
| 2019-05-30 | 개시 | Wolfe Research | Peer Perform |
| 2019-05-06 | 재확인 | Needham | Strong Buy |
| 2019-05-03 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-03 | 업그레이드 | UBS | Sell → Neutral |
| 2019-04-12 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2019-02-12 | 재확인 | BTIG Research | Buy |
| 2019-01-03 | 개시 | Needham | Strong Buy |
모두보기
Bruker Corp 주식(BRKR)의 최신 뉴스
Bruker (BRKR) and 10x Genomics Resolve Global Patent Dispute | B - GuruFocus
10x Genomics settles patent dispute with Bruker for $68 million - Investing.com
Bruker (BRKR) and 10x Genomics Settle Patent Disputes Globally - GuruFocus
Two Photon Microscope | Bruker Nano Surfaces | Products - Photonics Spectra
Bruker (BRKR) and 10x Genomics Settle Patent Dispute with Cross-License Agreement | BRKR Stock News - GuruFocus
Major Patent Battle Ends: Bruker and 10x Genomics Strike Global Deal to Protect Spatial Biology Innovation - Stock Titan
10x Genomics, Bruker Strike Deal After $31M Patent Verdict - Law360
10x, Bruker Settle Patent Suit on NanoString Gene-Mapping Tools - Bloomberg Law News
Repligen, Bruker, Agilent, Medpace, and Revvity Shares Skyrocket, What You Need To Know - Yahoo Finance
Bruker Corporation (BRKR): Among Michael Burry Stocks with Huge Upside Potential - Insider Monkey
Bruker Corporation (BRKR): A Bull Case Theory - MSN
Bruker Corporation (NASDAQ:BRKR) Q1 2025 Earnings Call Transcript - Insider Monkey
Stifel cuts Bruker stock price target to $48, maintains hold By Investing.com - Investing.com Canada
Bruker (BRKR) Sees Price Target Lowered to $45 by UBS | BRKR Stock News - GuruFocus
Bruker (BRKR): Barclays Maintains Rating but Lowers Price Target | BRKR Stock News - GuruFocus
Bruker (BRKR) Target Price Lowered by Goldman Sachs | BRKR Stock News - GuruFocus
Stifel cuts Bruker stock price target to $48, maintains hold - Investing.com
UBS Reduces Price Target for Bruker (BRKR) Amid Funding and Tariff Concerns | BRKR Stock News - GuruFocus
Bruker (BRKR) Stock Target Price Lowered by Stifel Analyst | BRKR Stock News - GuruFocus
Bruker (BRKR) Price Target Reduced by Stifel Amid Flat Growth Outlook | BRKR Stock News - GuruFocus
Bruker Q1 Earnings & Revenues Top Estimates, Stock Up, Margins Crash - Nasdaq
Barclays Adjusts Price Target for Bruker (BRKR), Maintains Overweight Rating | BRKR Stock News - GuruFocus
Bruker: Q1 Earnings Snapshot - New Haven Register
Bruker Corp (BRKR) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Market Challenges - Yahoo Finance
Bruker Corporation Navigates Growth Amidst Challenges - TipRanks
Earnings call transcript: Bruker Q1 2025 beats EPS, revenue forecasts - Investing.com
Compared to Estimates, Bruker (BRKR) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
Bruker (BRKR) Increases FY25 Revenue Forecast | BRKR Stock News - GuruFocus
Bruker (BRKR) Surpasses Q1 Revenue Expectations with Key Product Launches | BRKR Stock News - GuruFocus
Bruker Corp Q1 2025 Earnings: Revenue Surpasses Estimates at $80 - GuruFocus
Bruker’s (NASDAQ:BRKR) Q1 Sales Top Estimates, Full-Year Outlook Slightly Exceeds Expectations - Yahoo Finance
Bruker earnings beat by $0.05, revenue topped estimates - Investing.com
Bruker reports Q1 beat, lowers FY2025 guidance on market headwinds By Investing.com - Investing.com Canada
Bruker reports Q1 beat, lowers FY2025 guidance on market headwinds - Investing.com
Bruker Reports First Quarter 2025 Financial Results - Stock Titan
Nanorobots Market Size to Exceed USD 38,660 Million by 2034, Rising Demand for Targeted Drug Delivery is Driving Market Growth. - GlobeNewswire Inc.
Bruker announces majority acquisition of RECIPE, a leading provider of mass spectrometry-based diagnostic assay kits for therapeutic drug monitoring - Select Science
Bruker Corp. to Host Earnings Call - ACCESS Newswire
Bruker to launch Beacon Discovery at AACR 2025, expanding access to live single-cell functional analysis - Select Science
Bruker Spatial Biology Pushes Boundaries in Spatial Biology and Multiomics at AACR 2025 – Company Announcement - Financial Times
Bruker Spatial Biology Pushes Boundaries in Spatial Biology and Multiomics at AACR 2025 - Stock Titan
Bruker to Launch Beacon Discovery™ at AACR 2025, Expanding Access to Live Single-Cell Functional Analysis - Financial Times
Bruker Corporation (BRKR): Among Mid-Cap Stocks Insiders Were Buying in Q1 2025 - Insider Monkey
A Glimpse Into The Expert Outlook On Bruker Through 6 Analysts - Benzinga
Bruker to invest in German company RECIPE - Yahoo Finance
Bruker Introduces nVista 2P Miniature Microscope - Quantisnow
Bruker Introduces nVista 2P Miniature Microscope – Company Announcement - Financial Times
BRUKER CORP : Results of Operations and Financial Condition, Regulation FD Disclosure (form 8-K) - marketscreener.com
Bruker (BRKR) Acquires Majority Stake in RECIPE Chemicals + Instruments | BRKR Stock News - GuruFocus
Bruker Announces Majority Acquisition of RECIPE, a Leading Provider of Mass Spectrometry-based Diagnostic Assay Kits for Therapeutic Drug Monitoring - Yahoo Finance
Bruker's Strategic Move: $15M Revenue Diagnostics Firm RECIPE Acquisition Boosts Testing Portfolio - Stock Titan
Bruker Corp (BRKR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Bruker Corp 주식 (BRKR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Bures Thomas | Chief Accounting Officer |
Mar 10 '25 |
Buy |
47.40 |
500 |
23,698 |
3,472 |
| LAUKIEN FRANK H | PRESIDENT & CEO |
Feb 18 '25 |
Buy |
50.92 |
20,000 |
1,018,330 |
38,459,563 |
| PACKER RICHARD A | Director |
Dec 02 '24 |
Option Exercise |
19.12 |
10,000 |
191,200 |
84,254 |
| PACKER RICHARD A | Director |
Dec 02 '24 |
Sale |
57.82 |
3,350 |
193,683 |
80,904 |
2.22%
2.87%
자본화:
|
볼륨(24시간):